Drawing First Blood: Is MRD Testing Worthwhile in Myeloma?
Your source for worldwide news and
perspectives on hematology/oncology
july 2017
volume 03 | number 08
CONTENTS
Written in Blood
Enoxaparin Increases
ICH Risk in Glioma
Literature Scan
Blinatumomab Versus
Standard of Care in ALL
THE FDA
WEIGHS IN
Richard Pazdur, MD,
director of the FDA’s
Oncology Center of
Excellence, on the new
center’s innovative,
integrative efforts to
speed up the drug-
approval process
On Location
Highlights from the
2017 ASCO Annual
Meeting
Patient Education
Understanding
Blood Clots
DEPARTMENTS
6 UP FRONT
8 CLINICAL NEWS
31 TRAINING AND EDUCATION
36 FEATURES
44 BACK OF THE BOOK
www.ASHClinicalNews.org
The Society Pages:
Recent Promotions
and Transitions
Latest & Greatest:
New and Noteworthy
Research
Data Stream:
Health-Care Facts
and Figures